Based on the network pharmacological analysis, 9 hug targets (CCL2, IL10, PTGS2, TNF, MAPK1, IL6, CXCL8, TP53, and VEGFA) were collected and validated as the therapeutic targets of FHD on NS in vivo. The gene discussed is VEGFA; the disease is hypoalphalipoproteinemia, primary, 1.